Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208756 | 1.00 | NPC1 (0.46) | NPC1RAB9ACA12CA9MGLL | |
| Hydrochloric Acid SCHEMBL13684879 | 0.98 | NPC1 (0.45) | NPC1RAB9ACA12CA9MGLL | |
| SCHEMBL28128811 | 0.85 | AOC3 (0.44) | CA12CA9CA1CA2AOC3 | |
| SCHEMBL18624781 | 0.85 | AOC3 (0.44) | CA12CA9CA1CA2AOC3 | |
| SCHEMBL14868325 | 0.83 | AOC3 (0.46) | AOC3 | |
| SCHEMBL14868311 | 0.81 | NPC1 (0.51) | NPC1RAB9ACA12CA9MGLL | |
| SCHEMBL14868572 | 0.80 | ALOX5 (0.42) | — | |
| SCHEMBL14872587 | 0.80 | CAPN1 (0.35) | — | |
| SCHEMBL14868438 | 0.80 | ERCC1 (0.38) | RAB9ACA1CA2KMT2AALDH1A1 | |
| SCHEMBL14868579 | 0.80 | HSD11B1 (0.40) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464042-B2 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-10-11 | — | — | US | claimed |
| US-20150376123-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | IMMUNOMET THERAPEUTICS INC. | 2015-12-31 | — | — | US | claimed |
| US-9133110-B2 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2015-09-15 | — | — | US | claimed |
| US-20120309799-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2012-12-06 | — | — | US | claimed |
| EP-2522654-A2 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| US-9464042-B2 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150376123-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | IMMUNOMET THERAPEUTICS INC. | 2015-12-31 | — | — | US | disclosed |
| US-9133110-B2 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| US-20120309799-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376123-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | PRKAG1, PRKAG2, PRKAG3 | NPC1 380/4885RAB9A 2070/4885CA12 4069/4885 |
| US-20120309799-A1 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT | PRKAG1, PRKAG2, PRKAG3 | NPC1 380/4885RAB9A 2070/4885CA12 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.